Fusion Antibodies (LON:FAB) Shares Up 9.4% – Should You Buy?

Fusion Antibodies plc (LON:FAB) was up 9.4% during trading on Monday . The company traded as high as GBX 9.50 ($0.12) and last traded at GBX 9.30 ($0.11). Approximately 643,059 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 2,371,604 shares. The stock had previously closed at GBX 8.50 ($0.10).

Fusion Antibodies Trading Up 2.7 %

The firm has a market capitalization of £8.96 million, a price-to-earnings ratio of -235.00 and a beta of 0.49. The company has a fifty day moving average price of GBX 6.54 and a two-hundred day moving average price of GBX 4.64. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40.

Fusion Antibodies (LON:FAB) last released its quarterly earnings results on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) earnings per share for the quarter. Fusion Antibodies had a negative return on equity of 152.68% and a negative net margin of 195.95%. As a group, research analysts forecast that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.